Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine.

Cocaine Intermittent-access Long-access Rat Short-access Synthetic cathinones

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
11 Aug 2024
Historique:
received: 19 03 2024
revised: 23 07 2024
accepted: 06 08 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: aheadofprint

Résumé

Substance use disorder (SUD) is a heterogeneous disorder, where severity, symptoms, and patterns of use vary across individuals. Yet, when rats self-administer cocaine under short-access conditions, their behavior tends to be well-regulated, though individual differences can emerge with long- or intermittent-access. In contrast, significant individual differences emerge when rats self-administer 3,4-methylenedioxypyrovalerone (MDPV), even under short-access conditions, wherein ~30 % of rats exhibit high levels of drug-taking. This study assessed SUD-like phenotypes of male and female rats self-administering MDPV or cocaine by comparing level of drug intake, responding during periods of signaled drug unavailability, and sensitivity to footshock punishment to determine whether: (1) under short-access conditions, rats that self-administer MDPV will exhibit a more robust SUD-like phenotype than rats that self-administer cocaine; (2) female rats will have a more severe phenotype than male rats; and (3) compared to short-access, long- and intermittent-access to MDPV or cocaine self-administration will result in a more robust SUD-like phenotype. Compared to cocaine, rats that self-administered MDPV exhibited a more severe phenotype, even under short-access conditions. Long- and intermittent-access to cocaine and MDPV temporarily altered drug-taking patterns but did not systematically change SUD-like phenotypes. Behavioral and quantitative autoradiography studies suggest phenotypic differences are not due to expression of dopamine transporter, dopamine D

Identifiants

pubmed: 39141975
pii: S0376-8716(24)01333-4
doi: 10.1016/j.drugalcdep.2024.112408
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112408

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Michelle R Doyle (MR)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Nina M Beltran (NM)

Department of Psychology, University of Texas at El Paso, El Paso, TX, USA.

Mark S A Bushnell (MSA)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Maaz Syed (M)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Valeria Acosta (V)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Marisa Desai (M)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Kenner C Rice (KC)

Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism - Intramural Research Program, Bethesda, MD, USA.

Katherine M Serafine (KM)

Department of Psychology, University of Texas at El Paso, El Paso, TX, USA.

Georgianna G Gould (GG)

Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Lynette C Daws (LC)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Gregory T Collins (GT)

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; South Texas Veterans Health Care System, San Antonio, TX, USA. Electronic address: CollinsG@uthscsa.edu.

Classifications MeSH